SI3527563T1 - Inhibitorji DNA-PK - Google Patents
Inhibitorji DNA-PKInfo
- Publication number
- SI3527563T1 SI3527563T1 SI201431922T SI201431922T SI3527563T1 SI 3527563 T1 SI3527563 T1 SI 3527563T1 SI 201431922 T SI201431922 T SI 201431922T SI 201431922 T SI201431922 T SI 201431922T SI 3527563 T1 SI3527563 T1 SI 3527563T1
- Authority
- SI
- Slovenia
- Prior art keywords
- inhibitors
- dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361777816P | 2013-03-12 | 2013-03-12 | |
EP18207382.5A EP3527563B1 (en) | 2013-03-12 | 2014-03-12 | Dna-pk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3527563T1 true SI3527563T1 (sl) | 2022-01-31 |
Family
ID=50549437
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431922T SI3527563T1 (sl) | 2013-03-12 | 2014-03-12 | Inhibitorji DNA-PK |
SI201431104T SI2970218T1 (sl) | 2013-03-12 | 2014-03-12 | DNA-PK inhibitorji |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431104T SI2970218T1 (sl) | 2013-03-12 | 2014-03-12 | DNA-PK inhibitorji |
Country Status (26)
Country | Link |
---|---|
US (11) | US9340557B2 (sl) |
EP (3) | EP2970218B8 (sl) |
JP (2) | JP6360878B2 (sl) |
KR (1) | KR102216284B1 (sl) |
CN (2) | CN105246883B (sl) |
AU (2) | AU2014244555B2 (sl) |
BR (1) | BR112015021888B1 (sl) |
CA (1) | CA2904641C (sl) |
CY (2) | CY1121360T1 (sl) |
DK (2) | DK3527563T3 (sl) |
ES (2) | ES2900061T3 (sl) |
HK (1) | HK1220190A1 (sl) |
HR (2) | HRP20211855T1 (sl) |
HU (2) | HUE041544T2 (sl) |
IL (1) | IL241330B (sl) |
LT (2) | LT3527563T (sl) |
ME (1) | ME03336B (sl) |
MX (1) | MX365294B (sl) |
PL (2) | PL2970218T3 (sl) |
PT (2) | PT2970218T (sl) |
RS (2) | RS58374B1 (sl) |
RU (1) | RU2676259C2 (sl) |
SG (1) | SG11201507203RA (sl) |
SI (2) | SI3527563T1 (sl) |
TR (1) | TR201901886T4 (sl) |
WO (1) | WO2014159690A1 (sl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
DK3527563T3 (da) * | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
AU2016209321B2 (en) * | 2015-01-20 | 2019-05-09 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
PE20180020A1 (es) * | 2015-01-23 | 2018-01-09 | Glaxosmithkline Ip Dev Ltd | Compuestos |
CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
AR110770A1 (es) | 2017-01-23 | 2019-05-02 | Cadent Therapeutics Inc | Moduladores del canal de potasio |
CN107158001A (zh) * | 2017-03-29 | 2017-09-15 | 解益新 | 一种治疗哮喘的药物组合物 |
US20200361877A1 (en) * | 2018-01-17 | 2020-11-19 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
MA51619A (fr) * | 2018-01-17 | 2021-04-14 | Vertex Pharma | Inhibiteurs de la protéine kinase dépendante de l'adn |
IL276082B2 (en) * | 2018-01-17 | 2024-01-01 | Vertex Pharma | DNA-PK inhibitor compounds, preparations containing them and their uses |
SG11202107615TA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
CN111909147B (zh) * | 2019-05-10 | 2021-07-20 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
JP2022545921A (ja) | 2019-08-27 | 2022-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 反復dnaに関連する障害の治療のための組成物及び方法 |
CA3150516A1 (en) * | 2019-09-11 | 2021-03-18 | Provincial Health Services Authority | DNA-PK INHIBITOR COMPOUNDS |
WO2021072475A1 (en) * | 2019-10-15 | 2021-04-22 | Aucentra Therapeutics Pty Ltd | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions |
US20230018728A1 (en) * | 2019-11-21 | 2023-01-19 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof |
WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
BR112022021676A2 (pt) | 2020-04-28 | 2023-01-31 | Intellia Therapeutics Inc | Métodos de distribuição de célula in vitro |
JP2023542548A (ja) * | 2020-09-24 | 2023-10-10 | オークランド ユニサービシズ リミテッド | 新規アミノピリジン及びその癌治療への使用 |
BR112023016539A2 (pt) * | 2021-02-19 | 2023-11-14 | Kalvista Pharmaceuticals Ltd | Inibidores do fator xiia |
WO2022182959A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
EP4298222A1 (en) | 2021-02-26 | 2024-01-03 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
EP4305032A1 (en) * | 2021-03-10 | 2024-01-17 | Admare Therapeutics Society | 7-morpholino-1,6-naphthyridin-5-yl derivatives and pharmaceutical compositions thereof useful as dna-pk inhibitor |
EP4323360A1 (en) | 2021-04-17 | 2024-02-21 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571506A (en) | 1989-08-14 | 1996-11-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
DE69221175T2 (de) | 1991-02-07 | 1998-01-15 | Roussel Uclaf | Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
EP0519211A1 (de) | 1991-05-17 | 1992-12-23 | Hoechst Schering AgrEvo GmbH | Substituierte 4-Aminopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
AU3933493A (en) | 1992-04-24 | 1993-11-29 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal aminopyrimidines |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
DE4437406A1 (de) | 1994-10-19 | 1996-04-25 | Hoechst Ag | Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
DK0968206T3 (da) | 1997-02-19 | 2007-03-26 | Berlex Inc | N-heterocykliske derivater som NOS-inhibitorer |
JPH10251255A (ja) | 1997-03-14 | 1998-09-22 | Nissan Chem Ind Ltd | アジン誘導体 |
PL194980B1 (pl) | 1997-05-28 | 2007-07-31 | Aventis Pharma Inc | Nowe związki chinolinowe i chinoksalinowe, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie |
DE19801598C2 (de) | 1998-01-17 | 2000-05-11 | Aventis Res & Tech Gmbh & Co | Katalytische Synthese von N-alkylierten Anilinen aus Olefinen und Anilinen |
DE19836697A1 (de) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
AU2001234690A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001064646A2 (en) | 2000-03-01 | 2001-09-07 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20020111353A1 (en) | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
NZ526471A (en) | 2000-12-21 | 2005-08-26 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
JP2004521901A (ja) | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf阻害剤としてのピラゾール |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
MXPA03008888A (es) | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
MXPA03009378A (es) | 2001-04-13 | 2004-01-29 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas. |
EP1383771A1 (en) | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
EP1404669A2 (en) | 2001-05-16 | 2004-04-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
US6762179B2 (en) | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
DE60214703T2 (de) | 2001-06-01 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
WO2003004492A1 (en) | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
SG159380A1 (en) | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
US20030207873A1 (en) | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
KR20050006237A (ko) | 2002-05-06 | 2005-01-15 | 버텍스 파마슈티칼스 인코포레이티드 | 티아디아졸 또는 옥사디아졸 및 jak 단백질 키나제억제제로서의 이들의 용도 |
AU2003231880A1 (en) | 2002-05-30 | 2003-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
JP4570955B2 (ja) | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
RU2005106871A (ru) | 2002-08-14 | 2005-10-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы протеинкиназ и их применение |
US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
WO2004041789A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
CA2506773A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
WO2004058749A1 (en) | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
JP4808154B2 (ja) | 2003-03-13 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用な組成物 |
CA2523178C (en) | 2003-03-24 | 2012-10-23 | Luitpold Pharmaceuticals, Inc. | Materials and methods to potentiate cancer treatment |
US20040235834A1 (en) | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
US6875781B2 (en) | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
US7244735B2 (en) | 2003-12-02 | 2007-07-17 | Vertex Pharmaceuticals Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
ES2566973T3 (es) | 2004-03-15 | 2016-04-18 | Sunesis Pharmaceuticals, Inc. | Uso de SNS-595 para tratar leucemia |
GB0405985D0 (en) | 2004-03-17 | 2004-04-21 | Novartis Forschungsstiftung | Kinase |
ATE435858T1 (de) | 2004-05-14 | 2009-07-15 | Vertex Pharma | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
JP4449580B2 (ja) | 2004-05-31 | 2010-04-14 | 宇部興産株式会社 | 4−アラルキルアミノピリミジン誘導体及び抗菌剤 |
EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
ES2359007T3 (es) | 2004-09-17 | 2011-05-17 | Vertex Pharmaceuticals Incorporated | Compuestos de diaminotriazol útiles como inhibidores de proteínas quinasas. |
CA2582885A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
WO2006040568A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
WO2006050249A1 (en) | 2004-10-29 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Diaminotriazole compounds useful as inhibitors of protein kinases |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
JP2008523103A (ja) | 2004-12-14 | 2008-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkプロテインキナーゼのピリミジンインヒビターおよびその使用 |
EP1833820A1 (en) | 2004-12-23 | 2007-09-19 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinase and uses therof |
ES2776973T3 (es) | 2005-02-04 | 2020-08-03 | Firmenich Incorporated | Compuestos que comprenden restos de heteroarilo unidos y su uso como nuevos modificadores del sabor umami, saborizantes y potenciadores del sabor para composiciones comestibles |
MX2007012449A (es) | 2005-04-06 | 2007-12-05 | Irm Llc | Compuestos y composiciones que contienen diaril-amina, y su uso como moduladores de los receptores nucleares de hormonas esteroideas. |
AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
WO2006125616A2 (en) | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Pyrimidine-based cdk inhibitors for treating pain |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
JP2007008045A (ja) | 2005-06-30 | 2007-01-18 | Mitsui Chemicals Inc | 光記録媒体および1h−キノキサリン−2−オン誘導体 |
EP1906967A4 (en) | 2005-07-26 | 2010-07-28 | Vertex Pharma | ABL Kinase Inhibition |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
JP2009514875A (ja) | 2005-11-02 | 2009-04-09 | サイトキネティクス・インコーポレーテッド | 化学物質、組成物、および方法 |
CA2627857A1 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AU2006315334B2 (en) | 2005-11-16 | 2011-05-19 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US8013153B2 (en) | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008852A2 (en) | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
PT2044056E (pt) | 2006-07-14 | 2012-12-05 | Novartis Ag | Derivados de pirimidina como inibidores de alk-5 |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
EP2061764B1 (en) | 2006-08-22 | 2014-07-02 | Technion Research & Development Foundation LTD. | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
US7875603B2 (en) | 2006-09-21 | 2011-01-25 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
KR101101675B1 (ko) | 2006-10-02 | 2011-12-30 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
DE102006050512A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
CA2668429A1 (en) | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
EP2121662A1 (en) | 2006-12-04 | 2009-11-25 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
CA2673353A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
WO2008083346A1 (en) | 2006-12-28 | 2008-07-10 | Ambrx, Inc. | Phenazine and quinoxaline substituted amino acids and polypeptides |
PT2114900T (pt) | 2007-01-31 | 2019-01-17 | Ym Biosciences Australia Pty | Compostos à base de tiopirimidina e as suas utilizações |
WO2008106202A1 (en) | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
EP2134709A1 (en) | 2007-03-09 | 2009-12-23 | Vertex Pharmaceuticals, Inc. | Aminopyridines useful as inhibitors of protein kinases |
ES2435997T3 (es) | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
NZ579485A (en) | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
CA2682195A1 (en) | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7910587B2 (en) | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
CN101801959A (zh) | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
EP2155730A2 (en) | 2007-05-02 | 2010-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
US20100234386A1 (en) | 2007-05-10 | 2010-09-16 | Chaudhari Amita | Quinoxaline derivatives as pi3 kinase inhibitors |
WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
CN101687852A (zh) | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
WO2009004621A1 (en) | 2007-07-02 | 2009-01-08 | Technion Research & Development Foundation Ltd. | Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage |
US20100130597A1 (en) | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
UY31232A1 (es) * | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
JP5291624B2 (ja) | 2007-08-01 | 2013-09-18 | クミアイ化学工業株式会社 | オキソピラジン誘導体及び除草剤 |
US20090053192A1 (en) | 2007-08-10 | 2009-02-26 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
DE102007044032A1 (de) | 2007-09-14 | 2009-03-19 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
NZ584454A (en) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases |
CN101902912A (zh) | 2007-11-06 | 2010-12-01 | 纳幕尔杜邦公司 | 杀真菌杂环胺 |
EP2231624A4 (en) | 2007-12-21 | 2011-07-06 | Progenics Pharm Inc | TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR |
CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
EP2247580B1 (en) | 2008-03-05 | 2015-07-08 | Merck Patent GmbH | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
EP2298750A4 (en) | 2008-06-02 | 2012-04-25 | Msd Kk | NOVEL ISOXAZOLE DERIVATIVE |
DK2285786T3 (da) | 2008-06-16 | 2013-11-04 | Merck Patent Gmbh | Quinoxalindion-derivater |
EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
MX2011000839A (es) | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa. |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
EP2706057B1 (en) | 2008-12-05 | 2016-04-20 | Molecular Insight Pharmaceuticals, Inc. | Bis(imidazolyl)compounds and radionuclide complexes |
RU2016141566A (ru) | 2008-12-19 | 2018-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразина, используемые в качестве ингибиторов киназы atr |
CA2752150A1 (en) | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Selective kinase inhibitors |
JP2010111702A (ja) | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
CN105153188B (zh) | 2009-10-22 | 2018-06-01 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
ES2360333B1 (es) | 2009-10-29 | 2012-05-04 | Consejo Superior De Investigaciones Cientificas (Csic) (70%) | Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer |
WO2011052756A1 (ja) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソキサゾール誘導体 |
JP5002077B2 (ja) | 2009-12-25 | 2012-08-15 | 持田製薬株式会社 | 新規3−ヒドロキシ−5−アリールイソチアゾール誘導体 |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
BR112012022868A2 (pt) | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
TWI516264B (zh) | 2010-05-06 | 2016-01-11 | 臺北醫學大學 | 芳香醯喹啉化合物 |
JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ttk阻害作用を有する縮環ピラゾール誘導体 |
DE102010025786A1 (de) | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
CN107245056A (zh) | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
DE102011118830A1 (de) | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
DK3527563T3 (da) | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
-
2014
- 2014-03-12 DK DK18207382.5T patent/DK3527563T3/da active
- 2014-03-12 AU AU2014244555A patent/AU2014244555B2/en active Active
- 2014-03-12 PT PT14719434T patent/PT2970218T/pt unknown
- 2014-03-12 PL PL14719434T patent/PL2970218T3/pl unknown
- 2014-03-12 ME MEP-2019-55A patent/ME03336B/me unknown
- 2014-03-12 WO PCT/US2014/024767 patent/WO2014159690A1/en active Application Filing
- 2014-03-12 PL PL18207382T patent/PL3527563T3/pl unknown
- 2014-03-12 BR BR112015021888-1A patent/BR112015021888B1/pt active IP Right Grant
- 2014-03-12 MX MX2015012502A patent/MX365294B/es active IP Right Grant
- 2014-03-12 ES ES18207382T patent/ES2900061T3/es active Active
- 2014-03-12 TR TR2019/01886T patent/TR201901886T4/tr unknown
- 2014-03-12 EP EP14719434.4A patent/EP2970218B8/en active Active
- 2014-03-12 RS RS20190243A patent/RS58374B1/sr unknown
- 2014-03-12 RS RS20211467A patent/RS62649B1/sr unknown
- 2014-03-12 SG SG11201507203RA patent/SG11201507203RA/en unknown
- 2014-03-12 CN CN201480025199.1A patent/CN105246883B/zh active Active
- 2014-03-12 CN CN201710472183.0A patent/CN107200749B/zh active Active
- 2014-03-12 SI SI201431922T patent/SI3527563T1/sl unknown
- 2014-03-12 HU HUE14719434A patent/HUE041544T2/hu unknown
- 2014-03-12 EP EP21192836.1A patent/EP3985003B1/en active Active
- 2014-03-12 ES ES14719434T patent/ES2711839T3/es active Active
- 2014-03-12 PT PT182073825T patent/PT3527563T/pt unknown
- 2014-03-12 HR HRP20211855TT patent/HRP20211855T1/hr unknown
- 2014-03-12 LT LTEP18207382.5T patent/LT3527563T/lt unknown
- 2014-03-12 US US14/205,657 patent/US9340557B2/en active Active
- 2014-03-12 US US14/205,508 patent/US9359380B2/en active Active
- 2014-03-12 EP EP18207382.5A patent/EP3527563B1/en active Active
- 2014-03-12 KR KR1020157028350A patent/KR102216284B1/ko active IP Right Grant
- 2014-03-12 CA CA2904641A patent/CA2904641C/en active Active
- 2014-03-12 DK DK14719434.4T patent/DK2970218T3/en active
- 2014-03-12 JP JP2016501636A patent/JP6360878B2/ja active Active
- 2014-03-12 HU HUE18207382A patent/HUE057527T2/hu unknown
- 2014-03-12 SI SI201431104T patent/SI2970218T1/sl unknown
- 2014-03-12 LT LTEP14719434.4T patent/LT2970218T/lt unknown
- 2014-03-12 RU RU2015143211A patent/RU2676259C2/ru active
-
2015
- 2015-09-08 IL IL241330A patent/IL241330B/en active IP Right Grant
-
2016
- 2016-04-20 US US15/133,378 patent/US9987284B2/en active Active
- 2016-05-06 US US15/148,229 patent/US20160354381A1/en not_active Abandoned
- 2016-07-13 HK HK16108234.1A patent/HK1220190A1/zh unknown
-
2017
- 2017-07-25 US US15/659,306 patent/US10258627B2/en active Active
-
2018
- 2018-04-27 US US15/965,489 patent/US20180311254A1/en not_active Abandoned
- 2018-05-14 JP JP2018092924A patent/JP2018135389A/ja not_active Withdrawn
- 2018-09-27 AU AU2018236800A patent/AU2018236800B2/en active Active
-
2019
- 2019-02-20 CY CY20191100217T patent/CY1121360T1/el unknown
- 2019-02-21 US US16/282,083 patent/US10786512B2/en active Active
- 2019-02-26 HR HRP20190373TT patent/HRP20190373T1/hr unknown
- 2019-04-01 US US16/372,080 patent/US10973830B2/en active Active
-
2020
- 2020-09-17 US US17/023,597 patent/US11813267B2/en active Active
-
2021
- 2021-02-09 US US17/171,061 patent/US20210236505A1/en not_active Abandoned
- 2021-12-01 CY CY20211101051T patent/CY1125436T1/el unknown
-
2023
- 2023-02-27 US US18/175,515 patent/US20230277547A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190373T1 (hr) | Inhibitori dnk-pk | |
HRP20181862T1 (hr) | Inhibitori dna-pk | |
PT3057959T (pt) | Inibidores de adn-pk | |
HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
HK1216531A1 (zh) | 新的抑制劑 | |
GB201314578D0 (en) | Bicyclic inhibitors | |
GB201305503D0 (en) | Inhibitor |